EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing

EXELIXIS INC (NASDAQ:EXEL) has emerged as a compelling candidate for investors following the Minervini Trend Template and high-growth momentum strategies. The company, focused on developing oncology treatments, demonstrates strong technical and fundamental characteristics that align with these investment approaches.

Why EXEL Fits the Minervini Trend Template

The Minervini Trend Template identifies stocks in strong uptrends with favorable technical conditions. EXEL meets these criteria:

• Price Above Key Moving Averages: The stock trades at $43.37, well above its 50-day ($40.18), 150-day ($36.99), and 200-day ($34.86) moving averages.
• Upward-Trending Averages: The 150-day and 200-day moving averages are rising, confirming long-term strength.
• Relative Strength: With a ChartMill Relative Strength score of 94.95, EXEL outperforms nearly 95% of all stocks.
• Price Near 52-Week High: At $43.37, the stock is within 13% of its 52-week high ($49.62) and 99% above its 52-week low ($21.82).

These factors suggest EXEL is in a sustained uptrend, a key requirement for Minervini’s strategy.

High Growth Momentum Fundamentals

EXEL’s financial performance supports its growth potential:

• Earnings Growth: EPS (TTM) grew 205.6% year-over-year, with recent quarterly EPS growth at 175%.
• Revenue Growth: Revenue increased 24.5% over the past year, with consistent quarterly sales growth.
• Profit Margins: The company maintains strong profitability, with a trailing twelve-month profit margin of 24%.
• Analyst Upgrades: EPS estimates for the next year have been revised upward by 10.1% in the last three months, signaling improving expectations.

Technical Outlook

According to ChartMill’s technical analysis, EXEL has a perfect rating of 10, reflecting its strong trend and momentum. However, the setup quality score of 4 suggests waiting for a consolidation before entering. Key support levels are at $40.18-$40.45 and $37.72-$38.30.

For a deeper analysis, review the full technical report on EXEL.

Our High Growth Momentum + Trend Template screener lists more stocks with similar characteristics.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.